{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:54:18Z","timestamp":1781650458936,"version":"3.54.5"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Methicillin-resistant\n                      <jats:italic>Staphylococcus aureus<\/jats:italic>\n                      (MRSA) is highly prevalent in Saudi Arabia, posing a significant clinical challenge. International guidelines recommend empirical anti-MRSA coverage for high-risk patients. This study aimed to describe the real-world use of empirical anti-MRSA therapies and explore associated clinical outcomes among hospitalized adults at a single tertiary center in Saudi Arabia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective cohort study of 323 adult patients who received empirical intravenous anti-MRSA therapy (linezolid, vancomycin, or teicoplanin) between June 2021 and June 2025. The primary endpoint was in-hospital mortality. Secondary endpoints included clinical improvement, length of stay, adverse events, and changes in laboratory measures. Multivariable logistic regression was used to identify independent predictors of mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort had a mean age of 70.97 years, and 51.70% had started empirical anti-MRSA during ICU stay. Overall, the in-hospital mortality rate was 39.01%. Mortality rates did not differ significantly between treatment groups: 42.57% for linezolid, 35.82% for vancomycin, and 57.89% for teicoplanin (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.121). Changes in C-reactive protein varied significantly (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.009), with levels decreasing in the linezolid and vancomycin groups but increasing in the small teicoplanin group. Vancomycin was associated with a higher reported incidence of acute kidney injury than linezolid and teicoplanin (3.00% vs. 0.99% and 0.00%, respectively). In multivariable analysis, older age (OR 1.05,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and male sex (OR 1.81,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.032) were significant risk factors for mortality. Non-ICU admission was associated with a lower mortality rate (OR 0.45,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this real-world cohort of patients receiving empirical anti-MRSA therapy, we found no significant difference in in-hospital mortality or clinical improvement between linezolid, vancomycin, and teicoplanin. Patient outcomes were primarily driven by underlying factors like age and illness severity rather than the choice of antibiotics. Vancomycin was associated with a higher incidence of reported acute kidney injury. The findings highlight the need for improved antimicrobial stewardship to guide appropriate empirical therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13283-w","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T12:07:56Z","timestamp":1776341276000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical outcomes of empirical anti-MRSA therapy at a tertiary care center in Madinah, Saudi Arabia: a retrospective single-center cohort study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6496-4216","authenticated-orcid":false,"given":"Fatimah","family":"Aljohani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadiga","family":"Suliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa F.","family":"Alsehemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaf","family":"Kinani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roaa","family":"Alrehaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lamar","family":"Alkadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanan","family":"Alshareef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"13283_CR1","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children. Clin Infect Dis. 2011;52:e18\u201355. https:\/\/doi.org\/10.1093\/cid\/ciq146.","journal-title":"Clin Infect Dis"},{"key":"13283_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.22207\/JPAM.14.1.07","volume":"14","author":"MM Aljeldah","year":"2020","unstructured":"Aljeldah MM. Prevalence of Methicillin-Resistant Staphylococcus aureus (MRSA) in Saudi Arabia: A Systematic Review. J Pure Appl Microbiol. 2020;14:37\u201346. https:\/\/doi.org\/10.22207\/JPAM.14.1.07.","journal-title":"J Pure Appl Microbiol"},{"key":"13283_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.2174\/1874944501811010584","volume":"11","author":"KM Adam","year":"2019","unstructured":"Adam KM, Abomughaid MM. Prevalence of Methicillin-resistant Staphylococcus Aureus in Saudi Arabia Revisited: A Meta-analysis. Open Public Health J. 2019;11:584\u201391. https:\/\/doi.org\/10.2174\/1874944501811010584.","journal-title":"Open Public Health J"},{"key":"13283_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12879-023-08202-2","volume":"23","author":"A Azzam","year":"2023","unstructured":"Azzam A, Khaled H, Mosa M, Refaey N, AlSaifi M, Elsisi S, et al. Epidemiology of clinically isolated methicillin-resistant Staphylococcus aureus (MRSA) and its susceptibility to linezolid and vancomycin in Egypt: a systematic review with meta-analysis. BMC Infect Dis. 2023;23:263. https:\/\/doi.org\/10.1186\/s12879-023-08202-2.","journal-title":"BMC Infect Dis"},{"key":"13283_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/antibiotics14010024","volume":"14","author":"S Boucherabine","year":"2025","unstructured":"Boucherabine S, Nassar R, Mohamed L, Habous M, Nabi A, Husain RA, et al. Methicillin-Resistant Staphylococcus aureus: The Shifting Landscape in the United Arab Emirates. Antibiotics. 2025;14:24. https:\/\/doi.org\/10.3390\/antibiotics14010024.","journal-title":"Antibiotics"},{"key":"13283_CR6","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","volume":"47","author":"L Evans","year":"2021","unstructured":"Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181\u2013247. https:\/\/doi.org\/10.1007\/s00134-021-06506-y.","journal-title":"Intensive Care Med"},{"key":"13283_CR7","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1093\/cid\/ciw353","volume":"63","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;63:e61\u2013111. https:\/\/doi.org\/10.1093\/cid\/ciw353.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"13283_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1001\/jamainternmed.2019.7495","volume":"180","author":"BE Jones","year":"2020","unstructured":"Jones BE, Ying J, Stevens V, Haroldsen C, He T, Nevers M, et al. Empirical Anti-MRSA vs Standard Antibiotic Therapy and Risk of 30-Day Mortality in Patients Hospitalized for Pneumonia. JAMA Intern Med. 2020;180:552\u201360. https:\/\/doi.org\/10.1001\/jamainternmed.2019.7495.","journal-title":"JAMA Intern Med"},{"key":"13283_CR9","unstructured":"National AMR, Committee GAPHC. National antimicrobial therapy guidelines for community and hospital acquired infections in adults. Saudi MOH Ther Guidel Protoc. 2018; 1\u201365."},{"key":"13283_CR10","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1093\/cid\/cir895","volume":"54","author":"RG Wunderink","year":"2012","unstructured":"Wunderink RG, Niederman MS, Kollef MH, Shorr AF, Kunkel MJ, Baruch A, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012;54:621\u20139. https:\/\/doi.org\/10.1093\/cid\/cir895.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"13283_CR11","doi-asserted-by":"publisher","first-page":"R118","DOI":"10.1186\/cc13914","volume":"18","author":"P Peyrani","year":"2014","unstructured":"Peyrani P, Wiemken TL, Kelley R, Zervos MJ, Kett DH, File TMJ, et al. Higher clinical success in patients with ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus treated with linezolid compared with vancomycin: results from the IMPACT-HAP study. Crit Care. 2014;18:R118. https:\/\/doi.org\/10.1186\/cc13914.","journal-title":"Crit Care"},{"key":"13283_CR12","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1097\/CCM.0b013e3181eb3b96","volume":"38","author":"AC Kalil","year":"2010","unstructured":"Kalil AC, Murthy MH, Hermsen ED, Neto FK, Sun J, Rupp ME. Linezolid versus vancomycin or teicoplanin for nosocomial pneumonia: a systematic review and meta-analysis. Crit Care Med. 2010;38:1802\u20138. https:\/\/doi.org\/10.1097\/CCM.0b013e3181eb3b96.","journal-title":"Crit Care Med"},{"key":"13283_CR13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00228-014-1775-x","volume":"71","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zou Y, Xie J, Wang T, Zheng X, He H, et al. Linezolid versus vancomycin for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a systematic review employing meta-analysis. Eur J Clin Pharmacol. 2015;71:107\u201315. https:\/\/doi.org\/10.1007\/s00228-014-1775-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"13283_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ajem.2016.10.058","volume":"35","author":"H Takada","year":"2017","unstructured":"Takada H, Hifumi T, Nishimoto N, Kanemura T, Yoshioka H, Okada I, et al. Linezolid versus vancomycin for nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus in the elderly: A retrospective cohort analysis: Effectiveness of linezolid in the elderly. Am J Emerg Med. 2017;35:245\u20138. https:\/\/doi.org\/10.1016\/j.ajem.2016.10.058.","journal-title":"Am J Emerg Med"},{"key":"13283_CR15","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/IDR.S97416","volume":"10","author":"AO Althaqafi","year":"2017","unstructured":"Althaqafi AO, Matar MJ, Moghnieh R, Alothman AF, Alenazi TH, Farahat F, et al. Burden of methicillin-resistant Staphylococcus aureus pneumonia among hospitalized patients in Lebanon and Saudi Arabia. Infect Drug Resist. 2017;10:49\u201355. https:\/\/doi.org\/10.2147\/IDR.S97416.","journal-title":"Infect Drug Resist"},{"key":"13283_CR16","doi-asserted-by":"publisher","unstructured":"Kawasuji H, Nagaoka K, Tsuji Y, Kimoto K, Takegoshi Y, Kaneda M, et al. Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant staphylococcus aureus bacteremia: a systematic review and meta-analysis. Antibiot (Basel Switzerland). 2023;12. https:\/\/doi.org\/10.3390\/antibiotics12040697.","DOI":"10.3390\/antibiotics12040697"},{"key":"13283_CR17","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1378\/chest.10-1556","volume":"139","author":"AJ Walkey","year":"2011","unstructured":"Walkey AJ, O\u2019Donnell MR, Wiener RS. Linezolid vs Glycopeptide Antibiotics for the Treatment of Suspected Methicillin-Resistant Staphylococcus aureus Nosocomial Pneumonia. Chest. 2011;139:1148\u201355. https:\/\/doi.org\/10.1378\/chest.10-1556.","journal-title":"Chest"},{"key":"13283_CR18","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","volume":"24","author":"H Kato","year":"2021","unstructured":"Kato H, Hagihara M, Asai N, Shibata Y, Koizumi Y, Yamagishi Y, et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J Glob Antimicrob Resist. 2021;24:98\u2013105. https:\/\/doi.org\/10.1016\/j.jgar.2020.12.009.","journal-title":"J Glob Antimicrob Resist"},{"key":"13283_CR19","doi-asserted-by":"publisher","unstructured":"Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DD, Silva E. Teicoplanin versus vancomycin for proven or suspected infection. Cochrane database Syst Rev. 2010;CD007022. https:\/\/doi.org\/10.1002\/14651858.CD007022.pub2.","DOI":"10.1002\/14651858.CD007022.pub2"},{"key":"13283_CR20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s12879-022-07549-2","volume":"22","author":"JH Lee","year":"2022","unstructured":"Lee JH, Choi MG, Park HJ, Kim HC, Choi C-M. Comparison of mortality and clinical failure rates between vancomycin and teicoplanin in patients with methicillin-resistant Staphylococcus aureus pneumonia. BMC Infect Dis. 2022;22:600. https:\/\/doi.org\/10.1186\/s12879-022-07549-2.","journal-title":"BMC Infect Dis"},{"key":"13283_CR21","doi-asserted-by":"publisher","first-page":"866","DOI":"10.3390\/antibiotics13090866","volume":"13","author":"Q Liu","year":"2024","unstructured":"Liu Q, He D, Wang L, Wu Y, Liu X, Yang Y, et al. Efficacy and Safety of Antibiotics in the Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections: A Systematic Review and Network Meta-Analysis. Antibiotics. 2024;13:866. https:\/\/doi.org\/10.3390\/antibiotics13090866.","journal-title":"Antibiotics"},{"key":"13283_CR22","doi-asserted-by":"publisher","unstructured":"Zou F, Cui Z, Lou S, Ou Y, Zhu C, Shu C, et al. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol. 2024;15. https:\/\/doi.org\/10.3389\/fphar.2024.1338902.","DOI":"10.3389\/fphar.2024.1338902"},{"key":"13283_CR23","doi-asserted-by":"publisher","unstructured":"Hasan MJ, Nessa SST, Rabbani R. Comparative evaluation of linezolid and teicoplanin in the treatment of ventilator-associated MRSA pneumonia: a single-center experience. Int J Infect. 2020;7. https:\/\/doi.org\/10.5812\/iji.104447.","DOI":"10.5812\/iji.104447"},{"key":"13283_CR24","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.cmi.2020.07.016","volume":"26","author":"BJ Langford","year":"2020","unstructured":"Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2020;26:1622\u20139. https:\/\/doi.org\/10.1016\/j.cmi.2020.07.016.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"13283_CR25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/CM9.0000000000000166","volume":"132","author":"Q-H Chen","year":"2019","unstructured":"Chen Q-H, Shao J, Liu W-L, Wang H-L, Liu L, Gu X-H, et al. Predictive accuracy of Sepsis-3 definitions for mortality among adult critically ill patients with suspected infection. Chin Med J (Engl). 2019;132:1147\u201353. https:\/\/doi.org\/10.1097\/CM9.0000000000000166.","journal-title":"Chin Med J (Engl)"},{"key":"13283_CR26","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626\u201338. https:\/\/doi.org\/10.1038\/nri.2016.90.","journal-title":"Nat Rev Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13283-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13283-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13283-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:12:37Z","timestamp":1781647957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13283-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13283"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13283-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Prince Sultan Armed Forces Hospital \u2013 Madinah Research Ethics Committee granted ethical approval for the study (IRB: REC-25-13). The Prince Sultan Armed Forces Hospital \u2013 Madinah Research Ethics Committee waived the requirement for informed consent due to the retrospective nature of the data analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1039"}}